Scientists uncover how brain shrinkage across multiple regions accelerates memory decline in healthy ageing adults.

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...

Genetic treatments could be the key to unlocking some rare diseases. But bringing these medicines to patients involves ...

A massive international brain study has revealed that memory decline with age isn’t driven by a single brain region or gene, ...

Analysing thousands of MRI scans and memory tests from healthy adults, researchers found that memory loss accelerates as brain tissue shrinkage increases, especially later in life. While the ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

The sudden ascent of the AI therapist seems startlingly futuristic, as if it should be unfolding in some later time when the streets scrub themselves and we travel the world through pneumatic tubes.